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The use of image guidance is unlikely to result in an unacceptable 
increase in second cancer risk. 
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Purpose/Objective: Understanding the dose-response of the normal 
lung in order to minimize the risk of radiation pneumonitis (RP) is of 
critical importance for optimization of radiotherapy for lung cancer. 
In this study, we propose a method to combine the dose-response 
relationship for RP from the landmark QUANTEC paper with clinical 
risk factors in order to improve individual patient risk prediction. The 
approach is validated in an independent dataset of 103 patients. 
Materials and Methods: The prevalence of risk factors (pulmonary co-
morbidities, smoking history, age and chemotherapy) in the patient 
populations underlying the QUANTEC analysis was estimated, and a 
previously published method to adjust the dose-response relationship 
for clinical risk factors was employed. Estimates of effect size (odds 
ratios, OR) for clinical risk factors were drawn from a recently 
published meta-analysis. Baseline values for D50 (the dose resulting in 
a 50 % complication probability) and γ50 (the normalised slope of the 
dose-response curve at D50) were established. Confidence intervals 
were estimated using random sampling. The method was tested in an 
independent dataset (103 non-small cell lung cancer patients), 
comparing the predictive power of the dose-only QUANTEC model and 
the model taking risk factors into account. Subdistribution cumulative 
incidence functions for RP were compared in stratified analyses for 
patients with high / low risk predictions, based on group medians, 
from the two models, and concordance indices (c-indices) for the 
prediction of RP were calculated. C-indices were compared using a 
Student t-test for paired samples. 
Results: The logistic relationship between mean lung dose and the risk 
of RP was described in the QUANTEC paper by D50 = 30.8 Gy, γ50 = 
0.97. From this, a reference dose-response relationship for a patient 
without pulmonary co-morbidities, no history of smoking, below 63 
years old, and not treated with sequential chemotherapy was 
estimated as D050 = 32.3 Gy (95% CI: 28.9, 36.5), γ050 = 1.10 (95% CI: 
0.92, 1.31). ORs for each risk factor were then used to calculate 
individual patient risk estimates. The cumulative incidences of RP in 
the validation dataset were not significantly different in high / low 
risk patients stratified according to the QUANTEC model (p=0.11), but 
were significantly different using the individualized model (p=0.006, 
see Figure 1). The c-indices were significantly different between the 
dose-only and the individualized model (p=0.004 using binary risk 
allocation, p=0.04 using continuous NTCP as predictor). 
Conclusions: This study presents a method to combine a dose-
response function with known clinical risk factors, based on data from 
large, published meta-analyses. We demonstrate that the predictive 
power of the combined model is greater than a dose-only model in an 
independent dataset. This method, although not taking correlations 
between risk factors into account, allows for individualization of dose 
constraints and risk estimations, and it can easily be extended to 
include additional risk factors. 
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Purpose/Objective: (1) To prospectively determine the prevalence of 
patient-reported xerostomia after sparing the contralateral 
submandibular gland (cSMG) in oropharyngeal cancer patients without 
contralateral lymph node metastases. (2) To construct a normal tissue 
complication probability (NTCP) curve for submandibular gland(SMG) 
function after radiotherapy (RT) based on mean dose and selective 
flow measurements. 
Materials and Methods: 50 oropharyngeal cancer patients (cT1-4N0-
2bM0) were treated with an optimized IMRT-technique with the 
intention to spare both parotid glands (PGs) and the cSMG (aim cSMG 
<40 Gy; cSMG-sparing cohort). They were compared with a historical 
cohort of 52patients that received only PG-sparing IMRT (PG-sparing 
cohort). cSMG- and PGflow rates were measured 6 weeks and 1 year 
post-RT and converted into the percentage of baseline. Patient-
reported xerostomia was recorded using the EORTC QLQ-H&N35 single 
items xerostomia and sticky saliva. For NTCP-analysis, SMG flow data 
from a large patient cohort were fitted to the Lyman-Kutcher-Burman 
model with a complication defined as SMG flow ratio <25% of pre-RT 
flowrate (RTOG/EORTC grade 4 xerostomia). 
Results: cSMG mean dose could be reduced below 40 Gy in 50% and 
21% of the patients in the cSMG-sparing and PG-sparing cohorts (mean 
cSMG dose 39.1 vs 50.4 Gy) respectively. cSMG flow ratio, 
complication rate and xerostomia scores 1 year post-RT were slightly 
better in the cSMG-sparing cohort (ns). At 1 year, 56% of the patients 
from the cSMG-sparing cohort still reported grade 2-3 xerostomia.  
Post-hoc, patients were re-grouped according to mean cSMG dose 
above (n= 66) or below (n= 36) 40 Gy. All patients but one in the <40 
Gy group had a small (T1-T2) tumor and 53% received only unilateral 
neck-RT. Significantly higher cSMG flow ratios at 6 weeks and 1 year 
post-RT in the <40 Gy group translated into lower xerostomia scores at 
both time points (at 1 yr: 67 vs. 42% grade 2-3 xerostomia, p= 0.07). 
PG function (1 yr) was similar in both groups. LKB-modelling showed 
substantial shift of NTCP-curve between 6 weeks and 1 year post-RT: 
the TD50 (mean dose leading to 50% NTCP) was 23 and 35 Gy,resp. 
Above 40 Gy mean SMG dose, NTCP worsened between 6 weeks and 1 
year post-RT.  
See figure for the 1 year NTCP-curve. 
  
Conclusions: This study concerns the largest group of patients pub-
lished, for which a dose response curve for SMG-flow rate after radio-
therapy was analysed. cSMG mean doses below 40 Gy resulted in 
improved SMG function and reduced patient-reported xerostomia. 
Above 40 Gy submandibular function worsened in time. cSMG-sparing 
in oropharyngeal cancer patients(N-stages ≤N2b) is still challenging.  
 
 
 
